HER2 Low Breast Carcinoma

Explore clinical trials studying HER2 Low Breast Carcinoma. Study availability and eligibility vary by location and protocol.

7 public trials 5 recruiting studies

Refine in advanced search Browse all conditions

HER2 Low Breast Carcinoma trial results

Recruiting

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

NCT06224673

Conditions: Breast Diseases, Breast Neoplasms, HER2 Low Breast Carcinoma, +8 more
Locations: University of California, San Francisco San Francisco, California, United States

View Trial Details

Recruiting

ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

NCT07198724

Conditions: Breast Cancer, Breast Cancer Female, Breast Diseases, +8 more
Locations: Dana-Farber Cancer Institute Boston, Massachusetts, United States

View Trial Details

Recruiting

PRE-I-SPY Phase I/Ib Oncology Platform Program

NCT05868226

Conditions: Breast Diseases, Breast Neoplasms, ER Positive Breast Cancer, +29 more
Locations: The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center Birmingham, Alabama, United States

Moffitt Cancer Center Tampa, Florida, United States

The University of Chicago Medicine Comprehensive Cancer Center Chicago, Illinois, United States

UChicago Medicine Comprehensive Cancer Center at Silver Cross Hospital New Lenox, Illinois, United States

View Trial Details

Recruiting

A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer

NCT05911958

Conditions: HER2 Low Breast Carcinoma
Locations: Henan Cancer Hospital Zhengzhou, Henan, China

View Trial Details

Recruiting

Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd

NCT06298084

Conditions: Advanced Breast Cancer, Breast Cancer Metastatic, HER2 Low Breast Carcinoma, +1 more
Locations: Gustave Roussy Institut Villejuif, France

View Trial Details

Completed

Tumor Characteristics and Survival Rate of HER2-Low Breast Cancer Patients

NCT05754047

Conditions: Breast Diseases, Breast Neoplasms, HER2 Low Breast Carcinoma, +4 more
Locations: Not specified

View Trial Details

Active, Not Recruiting

Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer

NCT06144944

Conditions: Breast Cancer Invasive, Breast Diseases, Breast Neoplasms, +7 more
Locations: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Guangzhou, Guangdong, China

View Trial Details

HER2 Low Breast Carcinoma

HER2 Low Breast Carcinoma trial results

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

PRE-I-SPY Phase I/Ib Oncology Platform Program

A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer

Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd

Tumor Characteristics and Survival Rate of HER2-Low Breast Cancer Patients

Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer

Related conditions